General Information of Drug (ID: DMBRYZ7)

Drug Name
RG6292 Drug Info
Synonyms CD25 mAb
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMBRYZ7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Basiliximab DMWNRZT Organ transplant rejection NE84 Approved [3]
Inolimomab DMUS1F8 Heart transplant rejection NE84 Phase 3 [4]
RFT-5.dgA DMQ8K93 Human immunodeficiency virus infection 1C62 Phase 2 [5]
LMB-2 DMG7RAV Chronic lymphocytic leukaemia 2A82.0 Phase 2 [6]
CHT-25 DMJLZ8T Hodgkin lymphoma 2B30 Phase 1 [7]
HuMax-TAC DM8BSF3 Autoimmune diabetes 5A10 Terminated [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 2 receptor alpha (IL2RA) TT10Y9E IL2RA_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04158583) A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors.. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Roche.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.Biol Blood Marrow Transplant.2006 Nov;12(11):1135-41.
5 Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol. 2003 May;14(5):729-36.
6 Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.
7 A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710.
8 Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines. Med Res Rev. 2012 Mar;32(2):254-93.